A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience
Issue link: http://innovationscns.epubxp.com/i/425963
[ V O L U M E 1 1 , N U M B E R 9 – 1 0 , S E P T E M B E R – O C T O B E R 2 0 1 4 ] Innovations in CLINICAL NEUROSCIENCE 101 increase in psychotropic drug poisonings in adolescents and young adults since the FDA mandated boxed warnings on antidepressants used in t his population. 3 3 T he Pediatric versions of the S-STS have been linguistically validated for 6- to 8-year olds, 9- to 12- year olds, and 13- to 17-year olds, making them potentially useful tools for screening and tracking suicidality by school counselors. 9 CONCLUSION The S-STS has evolved to meet higher expectations for a safety and efficacy scale to assess and monitor suicidality in clinical, research, educational, and security settings. This update and the related appendices should provide clinicians, researchers, and those charged with the responsibility to assess and monitor suicidality in institutional settings, simple and clear answers to frequently asked questions on the current (2014) status of the scale. REFERENCES 1. United States Food and Drug Administration, United States Department of Health and Human Services. Guidance for Industry: Suicidality: Prospective Assessment of Occurrence in Clinical Trials, Draft Guidance. September 2010. https://www.federalregister.gov/articles/2010/ 09/09/2010-22404/draft-guidance-for- industry-on-suicidality-prospective- assessment-of-occurrence-in-clinical-trials. Accessed October 1, 2014. 2. United States Food and Drug Administration, United States Department of Health and Human Services. Guidance for Industry: Suicidality: Prospective Assessment of Occurrence in Clinical Trials, Draft Guidance. August 2012. Revision 1. http://www.fda.gov/downloads/Drugs/Guidan ces/UCM225130.pdf. Accessed October 1, 2014. 3. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS) [online]. 2010. www.cdc.gov/injury/wisqars/index.html. Accessed October 1, 2014. 4. Neeleman J. A continuum of premature death: meta-analysis of competing mortality in the psychosocially vulnerable. Int J Epidemiol. 2001;30(1):154–162. 5. Baerger DR. Risk management with the suicidal patient: lessons from case law. Prof Psychol Res Pract. 2001;32:359–66. 6. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, et al. The Mini International Neuropsychiatric Interview (M.I.N.I.): the d evelopment and validation of a structured diagnostic psychiatric interview. J Clin P sychiatry. 1998;59(suppl 20):22–33. 7 . Glossary. Health outcomes methodology. Medical Care. 2000;38(9 Suppl. II,II-7-II- 1 3):2–10. 8. Wyrwich KW, Wolinsky FD. Identifying m eaningful intra-individual change standards f or health-related quality of life measures. J Eval Clin Pract. 2000;6:39–49. 9 . Amado DM, Beamon DA, Sheehan DV. The l inguistic validation of the Pediatric versions of the Sheehan-Suicidality Tracking Scale ( S-STS). Innov Clin Neurosci 2014;11(9–10):141–163. 1 0. Posner K, Brown GK, Stanley B, et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency f indings from three multisite studies with adolescents and adults. Am J Psychiatry. 2 011;168:1266–1277. 1 1. Sheehan DV, Alphs L, Mao L. Comparative validation of the S -STS, the ISST-Plus, and the C-SSRS for assessing the suicidal thinking and behavior FDA 2012 cuicidality C ategories. Innov Clin Neurosci 2014;11(9–10):32–46. 1 2. Mundt JC, Greist JH, Gelenberg A, et al. F easibility and validation of a computer- automated Columbia-Suicide Severity Rating Scale using interactive voice response technology. J Psychiatr Res. 2010;44:1224–1228. 13. Coric V, Stock EG, Pultz J, et al. Sheehan-Suicidality Tracking Scale (S- STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry (Edgmont). 2009;6(1):26–31. 14. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164:1035–1043. 15. Preti A, Sheehan DV, Coric V, et al. Sheehan-Suicidality Tracking Scale (S-STS): reliability, convergent and discriminative validity in young Italian adults. Compr Psychiatry. 2013;54(7):842–849. 16. Youngstrom EA, Meyer R, Hameed A, Gelenberg A. Pennsylvania State study on the validation of the S-STS and the C-SSRS. Presented at 9th Annual Scientific Meeting. ISCTM. Washington, DC: February 19–21, 2013. 17. Lindenmayer JP, Czobor P, Alphs L, et al. The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res. 2003;63:161–170. 18. Alphs L, Sheehan DV, Mao L, et al. Validation of the ISST-Plus, the S-STS, and the C-SSRS for assessing suicidal thinking and behavior using mapping to the 2010 FDA Draft Guidance or C-CASA Categories. Poster presented at CNS Summit 2012. Boca Raton, FL: November 15–16, 2102. 19. Giddens JM, Sheehan KH, Sheehan DV. The Columbia-Suicide Severity Rating Scale (C- SSRS): Has the "Gold Standard" become a liability? Innov Clin Neurosci. 2014;11(9–10):66–80 20. Meyboom RHB, Egberts ACG, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Safety. 1 997;16(6):355–365. 21. Khan A, Khan SR, Hobus J, et al. Differential p attern of response in mood symptoms and s uicide risk measures in severely ill depressed patients assigned to citalopram w ith placebo or citalopram combined with lithium: role of lithium levels. J Psychiatr R es. 2011;45(11):1489–1496. 2 2. Coric V, Berman RM, Cedarbaum JM, Sheehan DV. Sheehan-Suicidality Tracking S cale in predementia Alzheimer's disease. P resented at 9th Annual Scientific Meeting. ISCTM. Washington, DC: February 19–21, 2 013. 23. Chappell P, Mahableshwarkar AR, Alphs L, e t al. ISCTM Suicidal Ideation and Behavior Assessment Workgroup. Prospective assessment of suicidal ideation and behavior: a n internet survey of pharmaceutical sponsor practices. Innov Clin Neurosci. 2 014;11(9–10):14–22. 2 4. Soma Initiative. M.I.N.I. Mini International Neuropsychiatric Interview. h ttp://www.soma-i.co.za/mini/default.asp. Accessed October 1, 2014. 25. National Institute of Mental Health and N euro Sciences. http://www.nimhans.kar.nic.in/ Accessed O ctober 1, 2014. 2 6. The Indian Express. Nimhans to conduct national mental health survey. http://indianexpress.com/article/india/india- others/nimhans-to-conduct-national-mental- health-survey/. Accessed October 1, 2014. 27. Kemp J, Bossarte R. Suicide Data Report: 2012. Department of Veterans Affairs, Mental Health Services, Suicide Prevention Program. http://www.va.gov/opa/docs/suicide-data- report-2012-final.pdf. Accessed October 1, 2014. 28. Hayes L. Suicide prevention in correctional facilities. In: Scott C, Gerbasi J (eds). Handbook of Correctional Mental Health. Washington, DC: American Psychiatric Publishing Inc.; 2005:69–88. 29. Mumola C. Suicide and Homicide in State Prisons and Local Jails. Bureau of Justice Statistics Special Report. Washington, DC: US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics; 2005. 30. Sheehan IS. Professor Sheehan. Sheehan research scales. http://professorsheehan.com/scales/Accessed October 1, 2014. 31. Merari A. Driven to Death: Psychological and Social Aspects of Suicide Terrorism. Oxford, UK: Oxford University Press; 2010. 32. Sheehan IS. Are suicide terrorists suicidal? Innov Clin Neurosci. 2014;11(9–10):81–92. 33. Lu CY, Zhang F, Lakoma MD et al. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ. 2014;348-g3596. (BMJ 2014;348:g3596 doi: 10.1136/bmj.g3596 (Published 18 June 2014).